Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers

NCT ID: NCT02393950

Last Updated: 2016-12-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-31
• Study Completion Date: 2016-03-31

Brief Summary

The study is a dose escalation study with 8 planned dose levels. The study is a 4-period crossover design where each healthy volunteer will be randomised to receive three dose levels of ODM-106 (single doses) and one dose of placebo. The study will look at the pharmacokinetics (how the body handles the drug) and pharmacodynamics (how the drug affects the body) of ODM-106.

Detailed Description

Eight planned dose levels of ODM-106 will be compared with placebo.There will be 2 panels of subjects with 4 dose levels in each panel. Subjects will be randomised to receive 3 dose levels of active treatment (single doses) and 1 dose of placebo. The dose levels will be escalated from the smallest dose upwards within the study and within the study subject. A third panel of 8 subjects may be included to investigate further dose levels of ODM-106, investigate the effect of taking ODM-106 with food or to compare two different formulations of ODM-106. For an individual subject, the study will consist of a screening period (maximum 4 weeks), 4 study treatment periods with a wash-out period between each study treatment administration and a post-treatment period of about 2 weeks.

The study duration for an individual will be approximately 12-16 weeks. Blood samples will be collected for the assessment of the concentration of ODM-106 and its metabolite.Plasma samples and cumulative urinary samples will be collected for metabolite screening. Safety will be assessed by a 12-lead electrocardiogram (ECG), continuous ECG monitoring, Holter ECG, supine and orthostatic blood pressure and heart rate, body temperature, physical examination, electroencephalogram (EEG), laboratory safety assessments and adverse events. Sedation and psychomotor tests and a quantitative EEG will also be performed.

Conditions

Healthy Volunteer Study

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: QUADRUPLE

Study Groups

Drug: ODM-106

Oral capsules dosage 2-800mg once daily for one day

Group Type: EXPERIMENTAL

ODM-106

Intervention Type: DRUG

Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.

Drug: Placebo

Oral capsules given once daily for one day

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.

Interventions

ODM-106

Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.

Intervention Type: DRUG

Placebo

Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Written informed consent obtained.
• Participants must be able to speak, read and understand German.
• Good general health ascertained by detailed medical history and physical examinations.
• Males 18-45 years (inclusive).
• Body mass index (BMI) 18-30 kg/m2 inclusive
• Weight 55-95 kg (inclusive).
• Participants with female partners of child-bearing potential must adhere to a proper form of contraception from first study treatment administration until 3 months after the end-of-study visit.

Exclusion Criteria

• A predictable poor compliance or inability to understand and comply with protocol requirements, instructions and protocol-stated restrictions or communicate well with the investigator.
• Vulnerable subjects.
• Veins unsuitable for repeated venipuncture.
• Evidence of clinically relevant cardiovascular, renal, hepatic, haematological, gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator. The participants should be healthy subjects.
• Subjects with a medical history of relevant psychiatric disorders or evidence of significant neuropsychiatric disease
• Any condition requiring regular concomitant medication including herbal products or likely to need any concomitant medication during the study.
• Definite or suspected personal history of hypersensitivity to drugs or excipients.
• Intake of any medication that could affect the outcome of the study, as judged by the investigator, within 2 weeks before first study treatment administration (2 months for enzyme inducing drugs like rifampicin or carbamazepin), or less than 5 times the half-life of the medication.
• A history of alcoholism or excess alcohol intake (including regular consumption of more than 21 units of alcohol per week) .
• Use of nicotine-containing products within 6 months of admission and inability to refrain from using nicotine-containing products during the study.
• History of drug abuse or positive drug screen for amphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, methamphetamine or methadone.
• Propensity to get headache when refraining from caffeine-containing beverages.
• Blood donation or loss of clinically relevant amount of blood within 2 months before the screening visit.
• Abnormal 12-lead ECG finding of clinical relevance at the screening visit
• Heart rate (HR) < 50 bpm or > 90 bpm after 10 min in rest (supine) at the screening visit
• At the screening visit: systolic BP < 90 mmHg or > 140 mmHg, diastolic BP < 50 mmHg or > 90 mmHg, orthostatic hypotension decrease of greater than or equal to 20 mmHg for systolic BP, decrease of greater than or equal to 10 mmHg for diastolic BP.
• Abnormal 24-h Holter of clinical relevance at the screening visit,
• Positive serology to human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies.
• Any abnormal value of laboratory, vital signs, or physical examination, which may in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk for the subject if he takes part in the study.
• Participation in an investigational drug study within 2 months before entry into this study.
• An employee, a direct or indirect relative of the employee of the contract research organisation or the sponsor.
• Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the subject.
• Subject with abnormal standard EEG judged as clinically relevant by the investigator at screening.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Orion Corporation, Orion Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rainard Fuhr, MD

Role: PRINCIPAL_INVESTIGATOR

Parexel International GmbH, Berlin, Germany

John Whiteside

Role: STUDY_DIRECTOR

Orion Corporation, Orion Pharma

Locations

Parexel International GmbH

Berlin, , Germany

Countries

Germany

Other Identifiers

2014-001317-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

3117001

Identifier Type: -

Identifier Source: org_study_id